DocMorris AG Shareholders Support Leadership Continuity at 2026 AGM

At the 2026 Annual General Meeting held in Zurich, DocMorris AG shareholders demonstrated strong support for the existing leadership and strategic direction. All Board of Directors' recommendations were endorsed, and their candidates were elected with clear majorities. Minority shareholder CEPD N.V.'s motions, aiming for greater influence on the Board, were decisively rejected.

Re-elected members Prof. Dr Andréa Belliger, Walter Oberhänsli, and Florian Seubert were joined by new independent experts Thomas Bucher, Nicole Formica-Schiller, and Dr Thomas U. Reutter on the Board. Walter Oberhänsli remains as Chairman.

DocMorris reported a 10.7% revenue growth in the first quarter, driven by prescription medicines and digital services. The AGM reaffirmed the goal to achieve EBITDA break-even by year-end 2026. Shareholders were assured of ongoing dialogue with stakeholders.